

Phil McEwan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1191614/publications.pdf>

Version: 2024-02-01

68
papers

2,252
citations

201385

27
h-index

233125

45
g-index

69
all docs

69
docs citations

69
times ranked

2422
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiorenal disease in the United States: future health care burden and potential impact of novel therapies. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2022, , 1-10.	0.5	3
2	Serum potassium variability as a predictor of clinical outcomes in patients with cardiorenal disease or diabetes: a retrospective UK database study. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 758-770.	1.4	5
3	Authorsâ€™ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”. <i>Pharmacoeconomics</i> , 2021, 39, 137-138.	1.7	0
4	Risk factors associated with the incidence and recurrence of hyperkalaemia in patients with cardiorenal conditions. <i>International Journal of Clinical Practice</i> , 2021, 75, e13941.	0.8	4
5	The effect of hyperkalemia and long inter-dialytic interval on morbidity and mortality in patients receiving hemodialysis: a systematic review. <i>Renal Failure</i> , 2021, 43, 241-254.	0.8	10
6	The cost-effectiveness of dapagliflozin in treating high-risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 1020-1029.	2.2	19
7	Ferric carboxymaltose for the treatment of iron deficiency in heart failure: a multinational cost-effectiveness analysis utilising AFFIRM-HF. <i>European Journal of Heart Failure</i> , 2021, 23, 1687-1697.	2.9	23
8	Associations between serum potassium and adverse clinical outcomes: A systematic literature review. <i>International Journal of Clinical Practice</i> , 2020, 74, e13421.	0.8	36
9	Identification of undiagnosed atrial fibrillation patients using a machine learning risk prediction algorithm and diagnostic testing (PULsE-AI): Study protocol for a randomised controlled trial. <i>Contemporary Clinical Trials</i> , 2020, 99, 106191.	0.8	14
10	Current challenges for assessing the long-term clinical benefit of cancer immunotherapy: a multi-stakeholder perspective. , 2020, 8, e000648.		15
11	The Impact of CKD Anaemia on Patients: Incidence, Risk Factors, and Clinical Outcomes” A Systematic Literature Review. <i>International Journal of Nephrology</i> , 2020, 2020, 1-21.	0.7	51
12	Resource use and direct medical costs of acute respiratory illness in the UK based on linked primary and secondary care records from 2001 to 2009. <i>PLoS ONE</i> , 2020, 15, e0236472.	1.1	7
13	Cost-effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health-economic analysis of DAPA-HF. <i>European Journal of Heart Failure</i> , 2020, 22, 2147-2156.	2.9	91
14	Assessing the cost-effectiveness of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus: A comprehensive economic evaluation using clinical trial and real-world evidence. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 2364-2374.	2.2	33
15	External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. <i>Pharmacoeconomics</i> , 2020, 38, 1123-1133.	1.7	11
16	Serum potassium as a predictor of adverse clinical outcomes in patients with increasing comorbidity burden. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2020, , .	1.8	5
17	Cost-effectiveness of dapagliflozin as an adjunct to insulin for the treatment of type 1 diabetes mellitus in the United Kingdom. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 1047-1055.	2.2	6
18	Relationship between hypoglycaemia, body mass index and quality of life among patients with type 1 diabetes: Observations from the DEPICT clinical trial programme. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 857-865.	2.2	6

#	ARTICLE	IF	CITATIONS
19	<p>Economic Evaluation of Single versus Combination Immuno-Oncology Therapies: Application of a Novel Modelling Approach in Metastatic Melanoma</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 241-252.	0.7	4
20	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 2019, 37, 1305-1312.	1.7	28
21	Predicting atrial fibrillation in primary care using machine learning. PLoS ONE, 2019, 14, e0224582.	1.1	88
22	Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21Â334 patients in the UK. ESC Heart Failure, 2019, 6, 280-290.	1.4	57
23	The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease. BMC Nephrology, 2019, 20, 31.	0.8	24
24	Assessing the Burden of Type 2 Diabetes in China Considering the Current Status-Quo Management and Implications of Improved Management Using a Modeling Approach. Value in Health Regional Issues, 2019, 18, 36-46.	0.5	14
25	Cohort versus patient level simulation for the economic evaluation of single versus combination immuno-oncology therapies in metastatic melanoma. Journal of Medical Economics, 2019, 22, 531-544.	1.0	15
26	A model to predict disease progression in patients with autosomal dominant polycystic kidney disease (ADPKD): the ADPKD Outcomes Model. BMC Nephrology, 2018, 19, 37.	0.8	34
27	Computer Modeling of Diabetes and Its Transparency: A Report on the Eighth Mount Hood Challenge. Value in Health, 2018, 21, 724-731.	0.1	63
28	FP371RECURRENT HYPERKALAEMIA AND ASSOCIATION WITH LENGTH-OF-STAY AND MORTALITY FOLLOWING HOSPITALISATION: REAL-WORLD EVIDENCE FROM UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i157-i157.	0.4	0
29	FP337RELATIONSHIP BETWEEN HYPERKALAEMIA AND DOWN-TITRATION OR DISCONTINUATION OF RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS IN UK PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2018, 33, i145-i145.	0.4	1
30	Modeling the economic outcomes of immuno-oncology drugs: alternative model frameworks to capture clinical outcomes. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 139-154.	0.7	13
31	Serum potassium as a predictor of adverse clinical outcomes in patients with chronic kidney disease: new risk equations using the UK clinical practice research datalink. BMC Nephrology, 2018, 19, 211.	0.8	34
32	An alternative approach to modelling <scp>HbA1c</scp> trajectories in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism, 2017, 19, 628-634.	2.2	5
33	Assessing the Budget Impact and Economic Outcomes of the Introduction of Daclatasvir + Asunaprevir and Sofosbuvir/Ledipasvir for the Treatment of Chronic Hepatitis C Virus Infection in Japan. Value in Health Regional Issues, 2017, 12, 1-6.	0.5	4
34	Modelling the Survival Outcomes of Immuno-Oncology Drugs in Economic Evaluations: A Systematic Approach to Data Analysis and Extrapolation. Pharmacoeconomics, 2017, 35, 1257-1270.	1.7	49
35	A clinicianâ€™s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective. European Journal of Gastroenterology and Hepatology, 2017, 29, 208-214.	0.8	5
36	Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea. PLoS ONE, 2017, 12, e0167770.	1.1	29

#	ARTICLE	IF	CITATIONS
37	Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. <i>Hepatology Research</i> , 2016, 46, 423-433.	1.8	22
38	Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting. <i>Pharmacoeconomics</i> , 2016, 34, 953-966.	1.7	25
39	The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus. <i>Diabetes Therapy</i> , 2016, 7, 825-845.	1.2	12
40	The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK. <i>European Journal of Gastroenterology and Hepatology</i> , 2016, 28, 173-180.	0.8	18
41	The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus. <i>PLoS ONE</i> , 2016, 11, e0162441.	1.1	10
42	Estimating the Clinical and Economic Benefit Associated with Incremental Improvements in Sustained Virologic Response in Chronic Hepatitis C. <i>PLoS ONE</i> , 2015, 10, e0117334.	1.1	21
43	Assessing the Long-Term Impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the Relationship between Treatment Uptake and Efficacy on Future Infections. <i>PLoS ONE</i> , 2015, 10, e0125846.	1.1	16
44	Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study. <i>PLoS ONE</i> , 2015, 10, e0134928.	1.1	15
45	Estimating Cost-Effectiveness in Type 2 Diabetes. <i>Medical Decision Making</i> , 2015, 35, 660-670.	1.2	13
46	Is antenatal screening for hepatitis C virus cost-effective? A decade's experience at a London centre. <i>Journal of Hepatology</i> , 2015, 63, 797-804.	1.8	42
47	Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice. <i>Journal of Comparative Effectiveness Research</i> , 2015, 4, 279-286.	0.6	3
48	Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries. <i>Primary Care Diabetes</i> , 2015, 9, 39-47.	0.9	36
49	Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. <i>Diabetes Therapy</i> , 2014, 5, 567-578.	1.2	10
50	Validation of the IMS CORE Diabetes Model. <i>Value in Health</i> , 2014, 17, 714-724.	0.1	163
51	Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands. <i>Clinical Drug Investigation</i> , 2014, 34, 135-146.	1.1	37
52	Review of Utility Values for Economic Modeling in Type 2 Diabetes. <i>Value in Health</i> , 2014, 17, 462-470.	0.1	165
53	Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b. <i>Value in Health Regional Issues</i> , 2014, 3, 136-145.	0.5	15
54	Assessing the Cost Utility of Response-Guided Therapy in Patients with Chronic Hepatitis C Genotype 1 in the UK Using the MONARCH Model. <i>Applied Health Economics and Health Policy</i> , 2013, 11, 53-63.	1.0	40

#	ARTICLE	IF	CITATIONS
55	The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States. <i>Hepatology</i> , 2013, 58, 54-64.	3.6	71
56	The Cost-Effectiveness of Saxagliptin Versus NPH Insulin When Used in Combination with Other Oral Antidiabetes Agents in the Treatment of Type 2 Diabetes Mellitus in Poland. <i>Diabetes Technology and Therapeutics</i> , 2012, 14, 65-73.	2.4	18
57	Cost Effectiveness of Saxagliptin and Metformin versus Sulfonylurea and Metformin in the Treatment of Type 2 Diabetes Mellitus in Germany. <i>Clinical Drug Investigation</i> , 2012, 32, 189-202.	1.1	38
58	Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden. <i>Primary Care Diabetes</i> , 2012, 6, 127-136.	0.9	37
59	Assessing the Relationship between Computational Speed and Precision. <i>Pharmacoeconomics</i> , 2010, 28, 665-674.	1.7	20
60	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK. <i>Current Medical Research and Opinion</i> , 2007, 23, S7-S19.	0.9	26
61	The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, S33-S39.	0.9	29
62	Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK. <i>Current Medical Research and Opinion</i> , 2007, 23, S21-S31.	0.9	27
63	The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. <i>Current Medical Research and Opinion</i> , 2007, 23, S41-S48.	0.9	28
64	Evaluation of the Cost Effectiveness of Sirolimus versus Tacrolimus for Immunosuppression Following Renal Transplantation in the UK. <i>Pharmacoeconomics</i> , 2006, 24, 67-79.	1.7	32
65	Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. <i>Current Medical Research and Opinion</i> , 2006, 22, 1523-1534.	0.9	236
66	Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster). <i>Current Medical Research and Opinion</i> , 2006, 22, 121-129.	0.9	69
67	Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years. <i>Current Medical Research and Opinion</i> , 2005, 21, 1793-1800.	0.9	10
68	Evaluation of the cost-effectiveness of Sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom. <i>Clinical Therapeutics</i> , 2005, 27, 1834-1846.	1.1	27